Our mission
and vision
Properly evaluate the values of pharmaceuticals
and medical devices.
Pharmacoeconomics (medical economic assessment) and health technology assessment (HTA) provide
important evidence for evaluation of values
and consideration of appropriate prices of pharmaceuticals and medical devices.
CRECON Medical Assessment Inc. (CMA) employs statistical analysis
and high-precision simulation for model construction and cost-effectiveness analysis.
CMA is committed to supporting the development of medical industries including pharmaceuticals
and medical devices by using its expertise.
Mission
Solve our clients’ problems with statistical analysis
and modeling technology.
Health and medical care should be prerequisites to human life.
To meet the expectations, the pharmaceuticals and medical device industries
are making efforts for research and development.
However, the cost-effectiveness of pharmaceuticals and medical devices is attracting attention
because of increasing medical expenses.
Thus, a new system for accurately evaluating their economic values is needed.
In April 2019, a system for examining cost-effectiveness was introduced
into the pricing rules for pharmaceuticals and medical devices.
We have been evaluating the values of pharmaceuticals and medical devices by utilizing our expertise
—statistical analysis and model construction
—we have gained over the years through pharmacoeconomics (medical economic assessment)
and health technology assessment (HTA).
Our mission is to offer numerous solutions to problems associated with pharmaceuticals and medical devices.
We are pursuing “value-based pricing” using cost-effectiveness analysis.
Vision
Highly motivated professionals
Consolidate the organization through the accumulation of knowledge and wisdom.
In Europe and the United States, pharmacoeconomics (medical economic assessment) and health technology assessment (HTA) are being put to practical use as de facto prerequisites.
Furthermore, in Japan, a system to examine cost-effectiveness was introduced into the pricing rules
for pharmaceuticals and medical devices in April 2019.
In the future, pharmacoeconomics and HTA should be urgently familiarized
in the pharmaceuticals and medical device industries.
However, it is difficult to collect various data required for analysis
and evaluate them accurately from a professional perspective.
We support efforts to assess cost-effectiveness in healthcare.
We are “highly motivated professionals.”
We aim to expand the foundation of the organization through accumulation of the latest expertise and wisdom.
We will continuously improve perspective for pharmacoeconomic and statistical analyses
to support the sustainable development of the pharmaceuticals and medical device industries.
